Cite
HARVARD Citation
Moriya, T. et al. (2022). Epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer. Interactive cardiovascular and thoracic surgery. pp. 416-423. [Online].